LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Sage Therapeutics Inc

Închisă

SectorSănătate

6.78 0.15

Rezumat

Modificarea prețului

24h

Curent

Minim

6.77

Maxim

6.85

Indicatori cheie

By Trading Economics

Venit

34M

-62M

Vânzări

1.2M

14M

EPS

-0.998

Marjă de profit

-442.395

Angajați

353

EBITDA

13M

-67M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+29.06% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-72M

415M

Deschiderea anterioară

6.63

Închiderea anterioară

6.78

Sentimentul știrilor

By Acuity

100%

0%

369 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Sage Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 iun. 2025, 14:31 UTC

Câștiguri

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 20:33 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 iun. 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 iun. 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 iun. 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 iun. 2025, 16:35 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:34 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 iun. 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 iun. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 iun. 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 iun. 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 iun. 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 iun. 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 iun. 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 iun. 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 iun. 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 iun. 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 iun. 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 iun. 2025, 14:12 UTC

Câștiguri

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 iun. 2025, 14:09 UTC

Câștiguri

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparație

Modificare preț

Sage Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

29.06% sus

Prognoză pe 12 luni

Medie 8.75 USD  29.06%

Maxim 12 USD

Minim 5 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSage Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

14 ratings

2

Cumpărare

11

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 7.285Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.